DF/HCC Program Affiliation

Prostate Cancer, Leader
Translational Pharmacology and Early Therapeutic Trials
Cancer Genetics

DF/HCC Associations

Principal Investigator, Prostate Cancer SPORE
Member, Clinical Science Coordinating Committee
Member, Center Scientific Council

Research Abstract

Our research team focuses on the molecular basis of genitourinary cancers and improved treatments for patients with prostate cancer, kidney cancer, bladder cancer, and testicular cancer. Laboratory research involves understanding the genetics of prostate cancer, while clinical research focuses on trials of novel therapeutics for genitourinary cancers.

In our laboratory, we have investigated germline and somatic genetic markers of prostate cancer phenotype.

Our clinical trials have focused on:
- introducing chemotherapy or novel therapeutics to patients with high-risk localized prostate cancer
- testing novel therapeutics in men with rising levels of prostate-specific antigen (PSA) following local therapy with agents such as rosiglitazone and celecoxib
- testing novel theraputics in men with advanced prostate disease
- treating renal cell carcinoma with antiVEGF-based therapies.

Publications

• D'Amico AV,Chen MH,Renshaw AA,Loffredo M,Kantoff PW.Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer.Cancer 2008 Dec 15;113(12):3290-7.
  18980297
• D'Amico AV,Chen MH,Renshaw AA,Loffredo B,Kantoff PW.Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.J Clin Oncol 2008 Jun 20;26(18):2979-83.
  18565884
• Tomlins S, Rhodes D, Yu J; Varambally S; Mehra R, Perner S, Demichelis F, Helgeson B, Laxman B, Morris D, Cao Q, Cao X, Andren O, Fall K; Johnson L, Wei J, Shah R, Al-Ahmadie H, Eastham J, Eggener S, Fine S, Hotakainen K, Stenman U, Tsodikov A, Gerald W,
• Setlur SR,Mertz KD,Hoshida Y,Demichelis F,Lupien M,Perner S,Sboner A,Pawitan Y,Andren O,Johnson LA,Tang J,Adami HO,Calza S,Chinnaiyan AM,Rhodes D,Tomlins S,Fall K,Mucci LA,Kantoff PW,Stampfer MJ,Andersson SO,Varenhorst E,Johansson JE,Brown M,Golub TR,Rubi
  18505969
• Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.Prostate specific antigen working group guidelines on prostate specific antigen doubling time.J Urol 2008 Jun;179(6):2181-6.
  18423743
• Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int 2008
  18399827
• Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M.Design and end points of clinical tria
  18309951
• Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR.Active surveillance for early-stage prostate cancer: review of the current literature.Cancer 2008 Apr 15;112(8
  18306379
• Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antig
  18293426
• D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW.p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a
  18291508
• Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.J Clin Oncol 2
  18281655
• D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW.Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.JAMA 2008 Jan 23;299(3):289-95.
  18212313
• Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andrén O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE, Rubin MA.Nine-gene molecular signature is not associated with prostate cancer death
  18199732
• Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.BJU Int 20
  18184327
• D'Amico AV, Kantoff PW, Chen MH.Aspirin and hormone therapy for prostate cancer.N Engl J Med 2007 Dec 27;357(26):2737-8.
  18160699
• Corsello SM, Kantoff PW.Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?.Nat Clin Pract Urol 2008 Feb;5(2):80-1.
  18087294
• McIntyre MH, Kantoff PW, Stampfer MJ, Mucci LA, Parslow D, Li H, Gaziano JM, Abe M, Ma J.Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms.Cancer Epidemiol Biomarkers Prev 2007 Nov;16(11):2233-6.
  18006911
• Keller ET, Rowley DR, Tomlins SA, Drake CG, Kantoff PW, Pienta KJ, Montie JE, Carter HB, Hruszkewicz AM, Gomez J, Mohla S, Getzenberg RH.Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.Cancer Res 2007 Oct 15
  17928375
• Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with s
  17893567
• Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC.Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.Nano Lett 2007 Oct;7(
  17854227
• Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA. .TMPRSS2:ERG Gene Fusion Associated with Lethal Prostate Cancer in a Watchful Waiting Cohort.Oncogene 07/23/2007;38(26):1-7.
• Ross RW, Kantoff PW.Predicting outcomes in prostate cancer: how many more nomograms do we need?.J Clin Oncol 2007 Aug 20;25(24):3563-4.
  17704399
• Mohler J, Babaian RJ, Bahnson RR, Boston B, D'Amico A, Eastham JA, Hauke RJ, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Logothetis C, MacVicar G, Pollack A, Pow-Sang JM, Roach M 3rd, Sandler H, Shrieve D, Srinivas S, Twardowski P, Urban DA, Wals
  17692170
• Hayes JH, Barry MJ, Kantoff PW, Stahl JE.Prostate-specific antigen screening for prostate cancer: a decision-analytical perspective.BJU Int 2007 Sep;100(3):486-8.
  17669139
• Avigan DE, Vasir B, George DJ, Atkins MB, McDermott DM, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II Study of Vaccination with Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients with Stage IV
• Cooperberg MR, Broering JM, Kantoff PW, Carroll PR.Contemporary trends in low risk prostate cancer: risk assessment and treatment.J Urol 2007 Sep;178(3 Pt 2):S14-9.
  17644125
• D'Amico AV, Goldhaber SZ; Chen MH, Loffredo M, RN, Renshaw AA, Loffredo B; PW Kantoff.Hormonal Therapy for Prostate Cancer and the Time Course to Cardiovascular Death.J Clin Oncol 06/10/2007;17(25):2420-5.
• Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J.Development of an integrated prostate cancer re
  16859581
• Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW.Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.J Clin Oncol 2006 Jun 20;24(18):2723-8.
  16782912
• Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R.Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci U S A 2006 Apr 18;103(16):6315-20.
  16606824
• Li H, Kantoff PW, Giovannucci E, Leitzmann M, Gaziano JM, Stampfer MJ, Ma J.Manganese Superoxide Dismutase (MnSOD) Polymorphism, Prediagnostic Plasma Antioxidants and Prostate Cancer Risk.Cancer Res:In press.
• Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW.A Phase I Study of estramustine, weekly docetaxel and carboplatin chemotherapy in patients with hormone refractory prostate cancer.Clinical Cancer Research:I
• Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen K, Stampfer MJ, Willett WC, Giovannucci E.Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the PSA era.Cancer epidemiology, biomarkers & preventi
• Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.The Prognostic Significance of Plasma Chromogranin A Levels in Hormone-Refractory Prostate Cancer Patients Treated on Cancer and Leukemia Group
• George D, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW.The Prognostic Significance of Plasma Interleukin-6 (IL-6) Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer (HRCaP): Results from CALGB 9480.Clinical Cancer
• Wang X,Yu J,Sreekumar A,Varambally S,Shen R,Giacherio D,Mehra R,Montie JE,Pienta KJ,Sanda MG,Kantoff PW,Rubin MA,Wei JT,Ghosh D,Chinnaiyan AM.Autoantibody signatures in prostate cancer.N Engl J Med 2005 Sep 22;353(12):1224-35.
  16177248
• Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW.Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radi
  15468186
• D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW.6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.JAMA 2004 Aug 18;29
  15315996
• Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR.Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.Proc Natl Acad Sci U S A 2003 Jun 24;100(13)
  12799464
• Halabi S,Small EJ,Hayes DF,Vogelzang NJ,Kantoff PW.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583.J Clin Oncol 2003 Feb 1;21(3):490-5
  12560440
• Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR.Gene expression correlates of clinical prostate cancer behavior.Cancer Cell 2002 Mar;1(2):203-9.
  12086878
• Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.J Clin Oncol 2001 Jun 15;19(12):3025-
  11408497
• Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ.Prognostic significance of reverse transcriptase polymerase chain reaction for prostate specific antigen in men with androgen independent prostate cancer.J Clin Oncol 06/15/2001;12(19):2238
• Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U
  10984506
• D'Amico AV, Schultz D, Loffredo M, Dugal R, Hurwitz M, Kaplan I, Beard CJ, Renshaw AA, Kantoff PW.Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.JAMA 2000
  10979115
• Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ.Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.J Clin Oncol 19
  10561316
• Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.Proc Natl Acad Sci U S A 1997 Apr 1;94(7):3320-3.
  9096391
• Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA.Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study.J Clin Oncol 1997 Jan;15(1):2
  8996146